Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Orally disintegrating tablets (ODTs) disintegrate immediately in the mouth so that patients can take it without water. This
characteristic of ODTs is beneficial for patients who have difficulty swallowing conventional tablets (CTs). Furthermore,
ingestion of ODTs without water may be beneficial for patients with an overactive bladder (OAB) who have lower urinary tract
symptoms and are thought to experience discomfort and inconvenience with water intake. Solifenacin (Vesicare®, VES) is an
antimuscarinic agent for the management of OAB. This study aimed to determine the amount of water required for ingesting
placebos of VES-ODT and of VES-CT. Healthy volunteers participated in this randomized crossover trial. The participants
were asked to drink water during the intake VES-CT and after the disintegration of VES-ODT in their oral cavity. The amounts
of water required for ingesting VES-CT and of VES-ODT were 42.8 mL and 20.0 mL, respectively, which indicated that the
amount of water required for ingesting ODTs was significantly lesser than that for ingesting CTs. Furthermore, 5 (16.7%)
participants did not require water for ingesting the ODTs. The amount of water required for taking 3 tablets was reduced
with increasing the number of ODTs (1, 2 or 3 ODTs). Clinical disintegration time of VES-ODT was 21.4 sec in 10 healthy
volunteers. This clinical disintegration time did not change significantly after unit-dose packaging or subsequent storage for
56 days. This study showed that the amount of water required for ingesting VES-ODT is lower than that for ingesting VES-CT.
Biography
Shinya Uchida, PhD, received his PhD degree from University of Shizuoka in 1999. He served as clinical pharmacist at University Hospital of Hamamatsu School
of Medicine. He is Associate Professor at University of Shizuoka and his major interests include clinical pharmaceutical science, clinical pharmacology and
pharmacokinetics. He has published more than 50 papers in reputed journals.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals